EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma

Sol Beccari, Esraa Mohamed, Viva Voong, Stephanie Hilz, Marisa Lafontaine, Anny Shai, Yunita Lim, Jerry Martinez, Benjamin Switzman, Ryon L Yu, Janine M Lupo, Edward F Chang und 4 weitere

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Sol Beccari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of California, San Francisco, California. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Signal Transduction, Proto-Oncogene Proteins c-akt, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, University of California, San Francisco, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarker-driven therapeutic clinical trials require the implementation of standardized, evidence-based practices for sample collection. In diffuse glioma, phosphatidylinositol 3 (PI3)-kinase/AKT/mTOR (PI3/AKT/mTOR) signaling is an attractive therapeutic target for which window-of-opportunity clinical trials could facilitate the identification of promising new agents. Yet, the relevant preanalytic variables and optimal tumor sampling methods necessary to measure pathway activity are unknown. To address this, we used a murine model for isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM) and human tumor tissue, including IDH-wildtype GBM and IDH-mutant diffuse glioma. First, we determined the impact of delayed time-to-formalin fixation, or cold ischemia time (CIT), on the quantitative assessment of cellular expression of 6 phosphoproteins that are readouts of PI3K/AK/mTOR activity (phosphorylated-proline-rich Akt substrate of 40 kDa (p-PRAS40, T246), -mechanistic target of rapamycin (p-mTOR; S2448); -AKT (p-AKT, S473); -ribosomal protein S6 (p-RPS6, S240/244 and S235/236), and -eukaryotic initiation factor 4E-binding protein 1 (p-4EBP1, T37/46). With CITs ≥ 2 hours, typical of routine clinical handling, all had reduced or altered expression with p-RPS6 (S240/244) exhibiting relatively greater stability. A similar pattern was observed using patient tumor samples from the operating room with p-4EBP1 more sensitive to delayed fixation than p-RPS6 (S240/244). Many clinical trials utilize unstained slides for biomarker evaluation. Thus, we evaluated the impact of slide storage conditions on the detection of p-RPS6 (S240/244), p-4EBP1, and p-AKT. After 5 months, storage at -80°C was required to preserve the expression of p-4EBP1 and p-AKT, whereas p-RPS6 (240/244) expression was not stable regardless of storage temperature. Biomarker heterogeneity impacts optimal tumor sampling. Quantification of p-RPS6 (240/244) expression in multiple regionally distinct human tumor samples from 8 patients revealed significant intratumoral heterogeneity. Thus, the accurate assessment of PI3K/AKT/mTOR signaling in diffuse glioma must overcome intratumoral heterogeneity and multiple preanalytic factors, including time-to-formalin fixation, slide storage conditions, and phosphoprotein of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesSignal TransductionProto-Oncogene Proteins c-aktBrain NeoplasmsGliomaHumansAnimalsMiceBiomarkers, TumorPhosphatidylinositol 3-KinasesDisease Models, AnimalSpecimen Handling

Stichwörter der Autor:innen

PI3/AKT/mTORbiomarkerdiffuse gliomaintratumoral heterogeneityphosphoproteinpreanalytic variables

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktMTOR protein, humanBiomarkers, TumorPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Neurological Surgery, University of California, San Francisco, California.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.
  • Department of Neurological Surgery, University of California, San Francisco, California; Neuropathology Division, Department of Pathology, University of California, San Francisco, California. Electronic address: Joanna.…

Förderung

  • NIH HHS
  • University of California, San Francisco
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Beccari, S., Mohamed, E., Voong, V., Hilz, S., Lafontaine, M., Shai, A., Lim, Y., Martinez, J., Switzman, B., Yu, R. L., Lupo, J. M., Chang, E. F., Hervey-Jumper, S. L., Berger, M. S., Costello, J. F., & Phillips, J. J. (2024). Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100488

Vancouver

Beccari S, Mohamed E, Voong V, Hilz S, Lafontaine M, Shai A, et al. Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100488

BibTeX
@article{Beccari2024,
  author = {Beccari, Sol and Mohamed, Esraa and Voong, Viva and Hilz, Stephanie and Lafontaine, Marisa and Shai, Anny and Lim, Yunita and Martinez, Jerry and Switzman, Benjamin and Yu, Ryon L and Lupo, Janine M and Chang, Edward F and Hervey-Jumper, Shawn L and Berger, Mitchel S and Costello, Joseph F and Phillips, Joanna J},
  title = {Quantitative Assessment of Preanalytic Variables on Clinical Evaluation of PI3/AKT/mTOR Signaling Activity in Diffuse Glioma},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100488}
}
Kostenlos starten →